- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The purpose of UNITAID is to contribute to the achievement of global long-term goals for HIV, tuberculosis and malaria through its interventions in product markets. These goals have determined the Strategic Objectives described in this Strategy for the coming four years and are shared by the international community at large.
Keywords: HIV/AIDS, TB, malaria, medicines, funding, diagnostics, prevention
The Global Price Reporting Mechanism (GPRM) contains information on transaction prices, sources and quantities of antiretroviral medicines (ARVs), tuberculosis and malaria drugs and HIV/AIDS, tuberculosis and malaria diagnostics purchased by HIV/AIDS, tuberculosis and malaria programmes in low-income countries1, lower middle-income countries2 and upper middle-income countries. Countries have been classified according to the World Bank Atlas calculation method.
Treatment 2015 provides a results-driven framework to expedite and greatly expand coverage. With less than 1000 days before the end of 2015, much work remains to be done. The WHO’s new 2013 guidelines on The Use of Antiretroviral Drugs for Treating and Preventing HIV Infection recommend a CD4 threshold of 500 for initiation of HIV treatment. As an important step towards getting to zero AIDS-related deaths, countries should be encouraged to prioritize immediate efforts to ensure that all people eligible for HIV treatment have access to it.
This publication reports on the progress being made in the global scale-up in the use of antiretroviral (ARV) medicines in low- and middle-income countries, the challenges that are being overcome or that await solutions and the opportunities for building on the achievements of the past decade.
This document provides guidance to countries for assessing the utility of data from programmes for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) for HIV sentinel surveillance (HSS) among pregnant women. The objectives of these guidelines are as follows:
BANGKOK, Thailand, 21 November 2013—United Nations entities, civil society networks and development partners in Asia and the Pacific are joining to urge for a rapid increase of voluntary confidential community-based HIV testing and counseling for key populations at higher risk—including men who have sex with men, transgender people, sex workers and people who use drugs— in the region, to help ensure more people in need are able to access life-saving antiretroviral treatment.
This paper documents the recent developments, opportunities and challenges in intellectual property rights and access to affordable medicines in China. In particular, the paper finds that there have been impressive achievements in the national response to the HIV epidemic in China. Examples include the rapid expansion of government-supported antiretroviral (ARV) schemes and the development of a legal framework on intellectual property to address access to affordable pharmaceutical products in China. Adoption of the National Intellectual Property Strategy by the State Council in June 2008, and the revisions to the Patent Law and the Implementing Regulations with strong focus on public health protection are among the most prominent legal and policy achievements over the recent years, founding an enabling environment for action.
This landscape report is part of an ongoing initiative within UNITAID to describe and monitor the landscape for HIV commodities. It provides a broad overview of key HIV prevention tools, describing market dynamics around such prevention technologies and the primary factors that affect commodity access in HIV-endemic countries. Specifically, the report describes and analyses the market and technology landscapes for (i) male circumcision devices, (ii) barrier methods, (iii) microbicides, (iv) antiretroviral-based methods and (v) commodities needed for harm reduction. The report also explores market-based interventions that could alleviate current market shortcomings to improve access, focusing on key emerging products and product areas that are rapidly evolving.
The present report focuses on certain forms of abuses in health-care settings that may cross a threshold of mistreatment that is tantamount to torture or cruel, inhuman or degrading treatment or punishment. It identifies the policies that promote these practices and existing protection gaps.
By illustrating some of these abusive practices in health-care settings, the report sheds light on often undetected forms of abusive practices that occur under the auspices of health-care policies, and emphasizes how certain treatments run afoul of the prohibition on torture and ill-treatment. It identifies the scope of State's obligations to regulate, control and supervise health-care practices with a view to preventing mistreatment under any pretext.
The purpose of this report is to highlight new developments and key challenges that UNITAID has faced as an organization and donor during 2012. This report will be the last to follow the Board approved key performance indicators (KPIs) set for the UNITAID Strategy 2010-2012. The report summarizes UNITAID’s results measured against the targets for 2012 set by its Executive Board at the beginning of the Strategy cycle for 2010-2012.
Keywords: HIV/AIDS, TB, malaria, medicines, diagnostics, ARV, treatment